Black Clover fans have been eagerly awaiting news about Season 5 since the anime went on hiatus in March 2021. With rumors swirling and excitement building, many are wondering: Is Black Clover Season ...

In a major development for the biopharma space, Glenmark Pharmaceuticals’ US-based innovation arm, IGI Therapeutics SA, has entered into an exclusive licensing agreement with global pharma giant ...

If you’re as hooked on Heartland as I am, you’re probably counting down the days until we get more of the Bartlett-Fleming family’s heartwarming adventures. This Canadian gem, set against the stunning ...

Tata Elxsi shares gained nearly 1% in early trade on Thursday, climbing to a high of ₹6,174 on the NSE, as investors await the company’s Q1 FY26 earnings. The stock opened at ₹6,130 and touched an ...

Emcure Pharmaceuticals Limited announced that its oncology manufacturing facility in Sanand, Ahmedabad has successfully cleared a Pre-Approval Inspection (PAI) conducted by the US Food and Drug ...

Alright, Sullivan’s Crossing fans, gather ‘round! That Season 3 finale had us all yelling at our screens—Maggie’s got a husband now? What?! If you’re as obsessed with this cozy Canadian drama, you’re ...

Alright, House of the Dragon fans, let’s talk about Season 3! After that jaw-dropping Season 2 finale, we’re all itching to know what’s next for the Targaryens and their dragon-filled civil war. The ...

Hey, Upload fans! If you’re anything like me, that Season 3 cliffhanger left you reeling, and you’re probably counting down the days until we get some answers in Season 4. The big question on everyone ...

Alright, Ginny & Georgia fans, let’s talk about the big question: Is Season 4 of Ginny & Georgia actually happening? After that wild Season 3 finale on Netflix (June 5, 2025, anyone?), we’re all dying ...

Pacifica Hotels G.K. subsidiary Karasuma Hospitality G.K. has signed a franchise agreement with IHG Hotels & Resorts to rebrand a 103-room hotel in a prime Kyoto location to Garner, IHG’s new midscale ...

Jefferies reiterated its ‘Buy’ rating on the stock with a target price of ₹100, stating that a higher HRAB could significantly enhance allowable tariff recovery and profitability for DIAL, addressing ...

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to ...